| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 9 | 2019 | 33 | 2.970 |
Why?
|
| Memory, Short-Term | 6 | 2019 | 149 | 2.240 |
Why?
|
| Cocaine | 6 | 2019 | 208 | 1.200 |
Why?
|
| Guanfacine | 2 | 2019 | 7 | 1.190 |
Why?
|
| Cocaine-Related Disorders | 7 | 2019 | 204 | 1.130 |
Why?
|
| Prefrontal Cortex | 12 | 2013 | 218 | 1.040 |
Why?
|
| Memory Disorders | 2 | 2019 | 235 | 1.010 |
Why?
|
| Cannabinoid Receptor Agonists | 2 | 2017 | 7 | 1.000 |
Why?
|
| Methamphetamine | 4 | 2016 | 48 | 0.950 |
Why?
|
| Spatial Behavior | 2 | 2014 | 14 | 0.820 |
Why?
|
| Dopamine Uptake Inhibitors | 4 | 2019 | 37 | 0.780 |
Why?
|
| Acetaldehyde Dehydrogenase Inhibitors | 1 | 2022 | 5 | 0.760 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2014 | 38 | 0.750 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2022 | 651 | 0.750 |
Why?
|
| Double-Blind Method | 11 | 2021 | 1665 | 0.740 |
Why?
|
| Disulfiram | 1 | 2022 | 34 | 0.740 |
Why?
|
| Citalopram | 2 | 2014 | 30 | 0.730 |
Why?
|
| Drug Therapy | 1 | 2022 | 94 | 0.730 |
Why?
|
| Food-Drug Interactions | 1 | 2021 | 11 | 0.720 |
Why?
|
| Alcoholic Beverages | 1 | 2021 | 18 | 0.720 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 2 | 2019 | 27 | 0.700 |
Why?
|
| Renal Elimination | 1 | 2020 | 10 | 0.680 |
Why?
|
| Psychomotor Performance | 3 | 2014 | 183 | 0.680 |
Why?
|
| Cannabidiol | 1 | 2020 | 22 | 0.680 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 128 | 0.680 |
Why?
|
| Blood Pressure | 7 | 2021 | 1421 | 0.680 |
Why?
|
| Endocannabinoids | 2 | 2018 | 44 | 0.680 |
Why?
|
| Acetazolamide | 1 | 2020 | 31 | 0.670 |
Why?
|
| Heart Rate | 5 | 2019 | 600 | 0.670 |
Why?
|
| Arthralgia | 1 | 2020 | 68 | 0.660 |
Why?
|
| Dog Diseases | 1 | 2020 | 60 | 0.660 |
Why?
|
| Ethanol | 1 | 2021 | 170 | 0.650 |
Why?
|
| Diuretics | 1 | 2020 | 169 | 0.630 |
Why?
|
| Alcoholism | 1 | 2022 | 253 | 0.620 |
Why?
|
| Drug Monitoring | 1 | 2020 | 181 | 0.610 |
Why?
|
| Osteoarthritis | 1 | 2020 | 104 | 0.610 |
Why?
|
| Behavior, Addictive | 3 | 2019 | 59 | 0.600 |
Why?
|
| Polyunsaturated Alkamides | 1 | 2018 | 29 | 0.600 |
Why?
|
| Arachidonic Acids | 1 | 2018 | 29 | 0.590 |
Why?
|
| Amidohydrolases | 1 | 2018 | 26 | 0.590 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2019 | 149 | 0.590 |
Why?
|
| Affect | 3 | 2019 | 172 | 0.590 |
Why?
|
| Comorbidity | 3 | 2022 | 1625 | 0.580 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 3 | 2008 | 20 | 0.540 |
Why?
|
| Dopamine | 11 | 2013 | 286 | 0.540 |
Why?
|
| Quinoxalines | 2 | 2014 | 40 | 0.540 |
Why?
|
| Psychotropic Drugs | 2 | 2012 | 130 | 0.540 |
Why?
|
| Benzazepines | 2 | 2014 | 61 | 0.530 |
Why?
|
| Medication Adherence | 1 | 2020 | 343 | 0.520 |
Why?
|
| Perindopril | 1 | 2016 | 2 | 0.520 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2019 | 1737 | 0.460 |
Why?
|
| Dopamine Agents | 1 | 2013 | 30 | 0.420 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 68 | 0.420 |
Why?
|
| Choice Behavior | 1 | 2014 | 137 | 0.400 |
Why?
|
| Sleep | 3 | 2025 | 370 | 0.400 |
Why?
|
| Male | 36 | 2025 | 66024 | 0.370 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2008 | 34 | 0.360 |
Why?
|
| Drug Users | 3 | 2016 | 10 | 0.360 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2019 | 102 | 0.360 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 2 | 2008 | 7 | 0.350 |
Why?
|
| Cannabinoids | 2 | 2018 | 33 | 0.350 |
Why?
|
| Adult | 20 | 2025 | 31959 | 0.350 |
Why?
|
| Anxiety | 2 | 2020 | 995 | 0.350 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2008 | 49 | 0.340 |
Why?
|
| Smoking Cessation | 2 | 2023 | 209 | 0.340 |
Why?
|
| Young Adult | 9 | 2025 | 9912 | 0.310 |
Why?
|
| Cannabis | 2 | 2020 | 52 | 0.300 |
Why?
|
| Administration, Intravenous | 3 | 2019 | 162 | 0.300 |
Why?
|
| Substance-Related Disorders | 1 | 2013 | 492 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 284 | 0.300 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 153 | 0.300 |
Why?
|
| Bipolar Disorder | 2 | 2023 | 367 | 0.290 |
Why?
|
| Discrimination Learning | 1 | 2008 | 23 | 0.290 |
Why?
|
| Appetitive Behavior | 1 | 2008 | 15 | 0.290 |
Why?
|
| Desipramine | 1 | 2008 | 27 | 0.290 |
Why?
|
| Association Learning | 1 | 2008 | 21 | 0.290 |
Why?
|
| Pilot Projects | 4 | 2021 | 1491 | 0.280 |
Why?
|
| Methylphenidate | 1 | 2008 | 58 | 0.280 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 237 | 0.280 |
Why?
|
| Macaca mulatta | 4 | 2014 | 513 | 0.270 |
Why?
|
| Humans | 34 | 2025 | 134037 | 0.250 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2005 | 7 | 0.250 |
Why?
|
| Middle Aged | 14 | 2025 | 29394 | 0.250 |
Why?
|
| Serotonin Agents | 1 | 2005 | 15 | 0.250 |
Why?
|
| Sleep Aids, Pharmaceutical | 1 | 2025 | 2 | 0.250 |
Why?
|
| Animals | 21 | 2020 | 36527 | 0.240 |
Why?
|
| Acetylcholine | 2 | 2003 | 87 | 0.240 |
Why?
|
| Mitragyna | 1 | 2025 | 14 | 0.240 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2018 | 30 | 0.230 |
Why?
|
| Attention | 2 | 2020 | 201 | 0.230 |
Why?
|
| Self Report | 4 | 2022 | 553 | 0.230 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2005 | 63 | 0.230 |
Why?
|
| Nicotinic Agonists | 4 | 2021 | 45 | 0.220 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 17 | 0.220 |
Why?
|
| Plant Extracts | 1 | 2025 | 138 | 0.220 |
Why?
|
| Receptors, Drug | 1 | 2003 | 40 | 0.210 |
Why?
|
| Female | 19 | 2025 | 71822 | 0.210 |
Why?
|
| Aging | 1 | 2011 | 1305 | 0.210 |
Why?
|
| Stress, Psychological | 3 | 2020 | 603 | 0.200 |
Why?
|
| Impulsive Behavior | 3 | 2025 | 161 | 0.200 |
Why?
|
| Reaction Time | 3 | 2014 | 181 | 0.200 |
Why?
|
| Prediabetic State | 1 | 2023 | 63 | 0.200 |
Why?
|
| Suicide | 1 | 2025 | 204 | 0.200 |
Why?
|
| Brain | 3 | 2021 | 3227 | 0.200 |
Why?
|
| Suicide, Attempted | 2 | 2025 | 154 | 0.190 |
Why?
|
| Rivastigmine | 2 | 2019 | 18 | 0.190 |
Why?
|
| Time Factors | 5 | 2019 | 6604 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2025 | 394 | 0.180 |
Why?
|
| Neuropsychological Tests | 4 | 2021 | 988 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2004 | 1310 | 0.170 |
Why?
|
| Reward | 1 | 2021 | 120 | 0.170 |
Why?
|
| Executive Function | 1 | 2021 | 124 | 0.170 |
Why?
|
| Analysis of Variance | 3 | 2019 | 1044 | 0.170 |
Why?
|
| Yoga | 1 | 2020 | 13 | 0.170 |
Why?
|
| Meditation | 1 | 2020 | 19 | 0.170 |
Why?
|
| Craving | 1 | 2019 | 15 | 0.160 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 473 | 0.160 |
Why?
|
| Nicotine | 4 | 2023 | 147 | 0.160 |
Why?
|
| Dogs | 1 | 2020 | 798 | 0.160 |
Why?
|
| Single-Blind Method | 1 | 2019 | 250 | 0.150 |
Why?
|
| Rats | 11 | 2005 | 3890 | 0.150 |
Why?
|
| Psychoses, Substance-Induced | 1 | 2018 | 8 | 0.150 |
Why?
|
| Nerve Net | 1 | 2021 | 260 | 0.150 |
Why?
|
| Schizophrenia | 2 | 2013 | 332 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2022 | 683 | 0.140 |
Why?
|
| Veterans | 2 | 2022 | 1782 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 139 | 0.140 |
Why?
|
| Varenicline | 2 | 2014 | 14 | 0.140 |
Why?
|
| Emergency Service, Hospital | 1 | 2025 | 1155 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2021 | 315 | 0.140 |
Why?
|
| Marijuana Smoking | 1 | 2017 | 33 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 470 | 0.130 |
Why?
|
| Nucleus Accumbens | 5 | 2003 | 55 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 209 | 0.130 |
Why?
|
| Students, Medical | 1 | 2021 | 363 | 0.130 |
Why?
|
| Doxazosin | 1 | 2016 | 20 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2022 | 13049 | 0.130 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 330 | 0.130 |
Why?
|
| Adolescent | 7 | 2023 | 20581 | 0.120 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2015 | 8 | 0.120 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 26 | 0.120 |
Why?
|
| Benzothiazoles | 1 | 2015 | 31 | 0.120 |
Why?
|
| Alkaloids | 1 | 2015 | 37 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 130 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1155 | 0.120 |
Why?
|
| Macaca fascicularis | 3 | 2013 | 89 | 0.120 |
Why?
|
| Dopamine Agonists | 1 | 2015 | 80 | 0.120 |
Why?
|
| Age Factors | 2 | 2019 | 2994 | 0.110 |
Why?
|
| Models, Biological | 1 | 2020 | 1537 | 0.110 |
Why?
|
| Inpatients | 1 | 2019 | 542 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 226 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 2299 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2014 | 27 | 0.110 |
Why?
|
| Phenylcarbamates | 1 | 2013 | 16 | 0.110 |
Why?
|
| Space Perception | 1 | 2014 | 63 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2013 | 24 | 0.110 |
Why?
|
| Benzoxazines | 2 | 2003 | 23 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2014 | 261 | 0.100 |
Why?
|
| Naphthalenes | 2 | 2003 | 37 | 0.100 |
Why?
|
| Headache | 1 | 2014 | 110 | 0.100 |
Why?
|
| Case-Control Studies | 3 | 2020 | 3660 | 0.100 |
Why?
|
| Morpholines | 2 | 2003 | 64 | 0.100 |
Why?
|
| Serotonin | 3 | 2005 | 226 | 0.100 |
Why?
|
| Analgesics | 2 | 2003 | 135 | 0.100 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 187 | 0.090 |
Why?
|
| Maze Learning | 1 | 2012 | 126 | 0.090 |
Why?
|
| Cell Line | 2 | 2008 | 2858 | 0.090 |
Why?
|
| Phencyclidine | 2 | 2002 | 6 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2015 | 727 | 0.090 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 99 | 0.080 |
Why?
|
| Hallucinogens | 2 | 2018 | 51 | 0.080 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2002 | 152 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 723 | 0.080 |
Why?
|
| Weight Gain | 2 | 2023 | 412 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4800 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2013 | 579 | 0.080 |
Why?
|
| Calcium Channel Blockers | 2 | 2013 | 117 | 0.080 |
Why?
|
| Reversal Learning | 1 | 2008 | 7 | 0.070 |
Why?
|
| Stereotyped Behavior | 1 | 2008 | 38 | 0.070 |
Why?
|
| Self Administration | 2 | 2019 | 45 | 0.070 |
Why?
|
| Injections, Intramuscular | 1 | 2008 | 198 | 0.070 |
Why?
|
| Corpus Striatum | 3 | 2003 | 97 | 0.070 |
Why?
|
| Aged | 3 | 2025 | 21750 | 0.070 |
Why?
|
| Stress, Physiological | 2 | 2000 | 272 | 0.070 |
Why?
|
| Mental Recall | 1 | 2008 | 143 | 0.070 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 252 | 0.070 |
Why?
|
| Microdialysis | 2 | 2003 | 57 | 0.060 |
Why?
|
| Ecological Momentary Assessment | 1 | 2025 | 10 | 0.060 |
Why?
|
| Binding, Competitive | 1 | 2005 | 194 | 0.060 |
Why?
|
| Individuality | 1 | 2025 | 37 | 0.060 |
Why?
|
| Depression | 1 | 2014 | 1363 | 0.060 |
Why?
|
| Stereoisomerism | 1 | 2005 | 119 | 0.060 |
Why?
|
| Norepinephrine | 1 | 2005 | 175 | 0.060 |
Why?
|
| Kinetics | 2 | 2005 | 1356 | 0.060 |
Why?
|
| Temperature | 1 | 2005 | 330 | 0.060 |
Why?
|
| Membrane Transport Proteins | 1 | 2005 | 187 | 0.050 |
Why?
|
| Receptors, Cannabinoid | 1 | 2003 | 10 | 0.050 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 34 | 0.050 |
Why?
|
| Transfection | 1 | 2005 | 1096 | 0.050 |
Why?
|
| Smokers | 1 | 2023 | 45 | 0.050 |
Why?
|
| Biogenic Monoamines | 1 | 2002 | 4 | 0.050 |
Why?
|
| Chronic Pain | 1 | 2025 | 149 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 19034 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 433 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2005 | 315 | 0.050 |
Why?
|
| Haloperidol | 2 | 2013 | 23 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2023 | 130 | 0.050 |
Why?
|
| Sex Factors | 1 | 2025 | 1387 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3752 | 0.040 |
Why?
|
| Premedication | 1 | 2001 | 42 | 0.040 |
Why?
|
| Receptors, Dopamine | 1 | 2001 | 41 | 0.040 |
Why?
|
| Nicotinic Antagonists | 1 | 2000 | 10 | 0.040 |
Why?
|
| Conditioning, Classical | 1 | 2001 | 53 | 0.040 |
Why?
|
| China | 1 | 2021 | 296 | 0.040 |
Why?
|
| Overweight | 1 | 2023 | 387 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 364 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2002 | 326 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 316 | 0.040 |
Why?
|
| Visual Analog Scale | 1 | 2019 | 7 | 0.040 |
Why?
|
| Fear | 1 | 2001 | 205 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2002 | 485 | 0.040 |
Why?
|
| Cerebellum | 1 | 2023 | 464 | 0.040 |
Why?
|
| Aggression | 1 | 2021 | 232 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 1164 | 0.040 |
Why?
|
| Electroshock | 1 | 1998 | 29 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 1218 | 0.040 |
Why?
|
| Foot | 1 | 1998 | 65 | 0.040 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 388 | 0.040 |
Why?
|
| Students | 1 | 2020 | 260 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 571 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2016 | 145 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 1996 | 48 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 124 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 1136 | 0.030 |
Why?
|
| Tryptophan | 1 | 1996 | 100 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 815 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 1998 | 522 | 0.030 |
Why?
|
| Child | 3 | 2023 | 25818 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 242 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2014 | 41 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 3998 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 86 | 0.030 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2013 | 20 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1996 | 300 | 0.030 |
Why?
|
| Berberine | 1 | 2013 | 10 | 0.030 |
Why?
|
| Visual Perception | 1 | 2014 | 136 | 0.030 |
Why?
|
| Monoacylglycerol Lipases | 1 | 2013 | 10 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2014 | 234 | 0.030 |
Why?
|
| Cholesterol | 1 | 1996 | 574 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2664 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2013 | 112 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 2683 | 0.020 |
Why?
|
| Obesity | 1 | 2023 | 2444 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 3853 | 0.020 |
Why?
|
| Risk Factors | 1 | 2025 | 11162 | 0.020 |
Why?
|
| Mecamylamine | 2 | 2000 | 10 | 0.020 |
Why?
|
| Immobilization | 2 | 2000 | 25 | 0.020 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 2 | 1998 | 9 | 0.020 |
Why?
|
| Phenethylamines | 1 | 2005 | 14 | 0.010 |
Why?
|
| Substantia Nigra | 1 | 2005 | 37 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 107 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 263 | 0.010 |
Why?
|
| Neostriatum | 1 | 2002 | 11 | 0.010 |
Why?
|
| Imipramine | 1 | 2002 | 18 | 0.010 |
Why?
|
| Fluoxetine | 1 | 2002 | 46 | 0.010 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2002 | 29 | 0.010 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 2000 | 4 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 2002 | 289 | 0.010 |
Why?
|
| Arousal | 1 | 2001 | 82 | 0.010 |
Why?
|
| Opioid Peptides | 1 | 2000 | 4 | 0.010 |
Why?
|
| Ventral Tegmental Area | 1 | 2000 | 49 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 5206 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2793 | 0.010 |
Why?
|
| Naloxone | 1 | 2000 | 51 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3979 | 0.010 |
Why?
|
| Narcotic Antagonists | 1 | 2000 | 112 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 3181 | 0.010 |
Why?
|
| Dihydroxyphenylalanine | 1 | 1998 | 8 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1998 | 74 | 0.010 |
Why?
|
| Injections | 1 | 1998 | 156 | 0.010 |
Why?
|
| Time | 1 | 1998 | 101 | 0.010 |
Why?
|
| Motor Activity | 1 | 2001 | 539 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 757 | 0.010 |
Why?
|
| Gerbillinae | 1 | 1996 | 55 | 0.010 |
Why?
|
| Hydroxylation | 1 | 1996 | 51 | 0.010 |
Why?
|